China Infectious Disease Drugs Market Report 2022 to 2030

China Infectious Disease Drugs Market Analysis

$ 3999

China Infectious Disease Drugs Market valued at $9.54 Bn in 2023, projected to reach $14.14 Bn by 2030 with a 5.77% CAGR. The industry is being driven by rising healthcare costs, technological innovation and advancements, and an aging population. The market is dominated by key players like Shanghai Fosun Pharmaceuticals, Sinovac Biotech, GlaxoSmithKline plc, AstraZeneca, AbbVie Inc., Gilead Sciences, Merck & Co., F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, and Janssen Pharmaceuticals.

ID: IN10CNPH012 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Aneri Parekh

Buy Now

China Infectious Disease Drugs Market Executive Summary

China Infectious Disease Drugs Market valued at $9.54 Bn in 2023, projected to reach $14.14 Bn by 2030 with a 5.77% CAGR.

China's Infectious Disease Drugs Market is focused on addressing numerous infectious diseases that are widespread in the country. This market covers a broad spectrum of drugs, such as respiratory infections, HIV/ AIDS, hepatitis, and tuberculosis, as well as antibiotics, antivirals, and antifungals. China continues to face issues related to antimicrobial resistance and infectious disease outbreaks, which fuels the need for novel treatments and efficient medications.

The rising demand for efficient treatments and rising awareness of infectious diseases are the main factors driving China's infectious disease drug market's steady growth. To launch novel medications and increase their market share, major players in the industry are concentrating on research and development. The expansion of the market is also being aided by government programs to enhance treatment accessibility and healthcare infrastructure.

In 2023, the global pharmaceutical market for infectious illnesses was valued at $118.75 Bn. This growth is due to an increase in diagnoses as well as government-sponsored public education efforts on infectious illness management and prevention. The increasing level of generic competition is indicative of a changing market situation. Long-term development, especially in developing nations, requires lowering financial obstacles and expanding access to treatment. More industry research and development will result from this.

Fosun Pharma is a market leader in infectious illness drugs, with a significant focus on research and development. Fosun Pharma is a major producer of Artesun® (Artesunate for Injection), a WHO-recommended first-line therapy for severe malaria. Their efforts had benefited almost 56 Mn people with severe malaria by the end of 2022. Fosun Pharma continually works to strengthen its position in the market by collaborating with other businesses and organizations. A prime example is their collaboration with the IFC to construct a pharmaceutical plant in Côte d'Ivoire, which aims to enhance Africa's access to vital medications.

China infectious disease drugs market

Market Dynamics

Market Growth Drivers:

Increasing Healthcare Expenditure: Chinese consumers are more eager to spend on healthcare as their income levels rise. This tendency is resulting in increased healthcare spending, particularly medications for the treatment of infectious diseases.

Technological Advancements and Innovation: The Chinese pharmaceutical business is expanding quickly and innovating rapidly. Rising R&D spending is resulting in more focused and effective treatments for infectious diseases, which is propelling market expansion.

Aging Population: As a result of China's rapidly aging population, age-related infectious disorders including influenza and pneumonia are more common, which is increasing demand for infectious disease medications.

Market Restraints:

Cultural factors: Cultural attitudes and behaviors about healthcare and traditional drug use might have an impact on the market and reduce demand for Western pharmaceutical products.

Intellectual Property Issues: Historically, China's protection of intellectual property has lagged behind that of Western nations, raising worries about theft and patent infringement. This may deter Chinese companies from investing in the study and creation of novel medications to treat infectious diseases.

Barriers to Market Access: For international businesses, breaking into the Chinese pharmaceutical industry can be difficult due to import limitations, taxes, and regional market preferences.

Healthcare Policies and Regulatory Landscape

The National Medical Products Administration (NMPA) is a national drug regulatory office under the State Council of China. The State Administration for Market Regulation is in charge of managing it. A New Drug Application (NDA) is sent by the applicant to the NMPA. The NMPA reviews the NDA before conducting an on-site inspection of the applicant's production facilities. The applicant may be requested to provide further clinical data or other relevant information by the NMPA. The NMPA's regulations are subject to frequent change, thus they require constant monitoring and modification. Other authorities may have different standards than the NMPA.

Competitive Landscape

Key Players:

Shanghai Fosun Pharmaceuticals
Sinovac Biotech
GlaxoSmithKline plc
AstraZeneca
AbbVie Inc.
Gilead Sciences
Merck & Co.
F. Hoffman-La Roche Ltd.
Boehringer Ingelheim International GmbH
Janssen Pharmaceuticals

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Drug Market Segmentation

By Disease

HIV
Influenza
Hepatitis
Tuberculosis
Malaria
Other

By Treatment

Antibacterial
Antiviral
Antiparasitic
Other

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.